1-3 of 3
Markus Hansson
Close
Sort by
Journal Articles

Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial

Clinical Trials & Observations
Rowan Kuiper, Sonja Zweegman, Mark van Duin, Martin H. van Vliet, Erik H. van Beers, Belinda Dumee, Michael Vermeulen, Jasper Koenders, Bronno van der Holt, Heleen Visser-Wisselaar, Markus Hansson, Annette W. G. van der Velden, H. Berna Beverloo, Marian Stevens-Kroef, Mark-David Levin, Annemiek Broijl, Anders Waage, Pieter Sonneveld
Journal: Blood Advances
Blood Adv (2020) 4 (24): 6298–6309.
https://doi.org/10.1182/bloodadvances.2020002838
Published: 2020
Includes: Supplemental data
Journal Articles

Search for multiple myeloma risk factors using Mendelian randomization

Molly Went, Alex J. Cornish, Philip J. Law, Ben Kinnersley, Mark van Duin, Niels Weinhold, Asta Försti, Markus Hansson, Pieter Sonneveld, Hartmut Goldschmidt, Gareth J. Morgan, Kari Hemminki, Björn Nilsson, Martin Kaiser, Richard S. Houlston
Journal: Blood Advances
Blood Adv (2020) 4 (10): 2172–2179.
https://doi.org/10.1182/bloodadvances.2020001502
Published: 2020
Includes: Supplemental data
Journal Articles

Direct evidence for a polygenic etiology in familial multiple myeloma

Britt-Marie Halvarsson, Anna-Karin Wihlborg, Mina Ali, Konstantinos Lemonakis, Ellinor Johnsson, Abhishek Niroula, Carrie Cibulskis, Niels Weinhold, Asta Försti, Evren Alici, Christian Langer, Michael Pfreundschuh, Hartmut Goldschmidt, Ulf-Henrik Mellqvist, Ingemar Turesson, Anders Waage, Kari Hemminki, Todd Golub, Hareth Nahi, Urban Gullberg, Markus Hansson, Björn Nilsson
Journal: Blood Advances
Blood Adv (2017) 1 (10): 619–623.
https://doi.org/10.1182/bloodadvances.2016003111
Published: 2017
Includes: Supplemental data